ConductScience.org, home

Paper42469710

Non-steroidal mineralocorticoid receptor antagonists in non-diabetic kidney disease: a narrative review of mechanisms and clinical advances.

Luo F and 5 others. BMC Nephrol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Non-steroidal mineralocorticoid receptor antagonists in non-diabetic kidney disease: a narrative review of mechanisms and clinical advances. Papers, record 42469710. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42469710

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Non-steroidal mineralocorticoid receptor antagonists in non-diabetic kidney disease: a narrative review of mechanisms and clinical advances.
PubMed
Journal
BMC Nephrol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-10-16
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Luo FFei
2Hu JJingjia
3Fang HHongliang
4Li XXianfa
5Zhu CCaifeng
6Bao ZZiyang

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Mineralocorticoid Receptor AntagonistsMajor topic
Renal Insufficiency, ChronicMajor topic
Humans
Renin-Angiotensin System
Naphthyridines
Proteinuria

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
ZD20240019;GZY-KJS-ZJ-2025-055
Hangzhou Municipal Health Science and Technology Key Project(grant number:ZD20240019);Joint TCM Science & Technology Projects of National Demonstration Zones for Comprehensive TCM Reform(grant number:GZY-KJS-ZJ-2025-055);Hangzhou "Two-way Open Bidding" Co-construction Project for Medical Specialty
PubMed

Source PubMed

Download CSV of grants

References81

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139537335Primary glomerular diseases and long-term adverse health outcomes: A nationwide cohort study.J Intern Med2025https://conductscience.org/library/papers/39537335PubMed
237875671The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone.Clin Pharmacokinet2023https://conductscience.org/library/papers/37875671PubMed
318404673A comparison of the aldosterone-blocking agents eplerenone and spironolactone.Clin Cardiol2008https://conductscience.org/library/papers/18404673PubMed
439907538Mineralocorticoid receptor antagonism for non-diabetic kidney disease.Nephrol Dial Transplant2025https://conductscience.org/library/papers/39907538PubMed
539248263
Mineralocorticoid Receptor Blocker Prevents Mineralocorticoid Receptor-Mediated Inflammation by Modulating Transcriptional Activity of Mineralocorticoid Receptor-p65-Signal Transducer and Activator of Transcription 3 Complex.
J Am Heart Assoc2024https://conductscience.org/library/papers/39248263PubMed
612167587Concerted action of ENaC, Nedd4-2, and Sgk1 in transepithelial Na(+) transport.Am J Physiol Renal Physiol2002https://conductscience.org/library/papers/12167587PubMed
741005568Mineralocorticoid receptor inhibition in parietal epithelial cells prevents focal segmental glomerulosclerosis and crescentic glomerulonephritis.Kidney Int2025https://conductscience.org/library/papers/41005568PubMed
837906287Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists.J Clin Invest2024https://conductscience.org/library/papers/37906287PubMed
938186886Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial.Clin Kidney J2024https://conductscience.org/library/papers/38186886PubMed
1041206667Efficacy and safety of finerenone with SGLT2i in IgA nephropathy.Nephrol Dial Transplant2026https://conductscience.org/library/papers/41206667PubMed
1141301427Regulation of Klotho Production by Mineralocorticoid Receptor Signaling in Renal Cell Lines.Biomolecules2025https://conductscience.org/library/papers/41301427PubMed
1241332164Effect of finerenone on proteinuria reduction in IgA nephropathy.Ren Fail2025https://conductscience.org/library/papers/41332164PubMed
1336351458Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.Lancet2022https://conductscience.org/library/papers/36351458PubMed
1422301619Inducible kidney-specific Sgk1 knockout mice show a salt-losing phenotype.Am J Physiol Renal Physiol2012https://conductscience.org/library/papers/22301619PubMed
1526361797Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia.J Am Soc Nephrol2016https://conductscience.org/library/papers/26361797PubMed
1640366120Spironolactone protects against hypertension-induced renal fibrosis by promoting autophagy and inhibiting the NLRP3 inflammasome.J Hypertens2025https://conductscience.org/library/papers/40366120PubMed
1741573738Comparative safety profiles of spironolactone, eplerenone, and finerenone: a pharmacovigilance study based on FAERS data from 2004 to 2024.Front Pharmacol2025https://conductscience.org/library/papers/41573738PubMed
1829548765The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling.Kidney Int2018https://conductscience.org/library/papers/29548765PubMed
1942171960Finerenone in Cardiorenal Disease: A Narrative Review of Molecular Mechanisms, Clinical Evidence, and Emerging Therapeutic Roles.Cardiovasc Drugs Ther2026https://conductscience.org/library/papers/42171960PubMed
2041351406Aldosterone-Induced Renal Lymphangiogenesis and Endothelial-To-Mesenchymal Transformation to Promote Renal Interstitial Fibrosis Through the MR/TGF-β1 Pathway in Mice.Front Biosci (Landmark Ed)2025https://conductscience.org/library/papers/41351406PubMed

See all 81 referencesDownload CSV of references

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
NR3C24306PubTator's text mininghttps://conductscience.org/library/genes/4306NCBI Gene
REN5972PubTator's text mininghttps://conductscience.org/library/genes/5972NCBI Gene
SLC5A26524PubTator's text mininghttps://conductscience.org/library/genes/6524NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42469710

GET https://conductscience.org/api/papers/v1/42469710/references?page=2